Virtus Biotech ETF
2 hedge funds and large institutions have $1.96M invested in Virtus Biotech ETF in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.96M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$994 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1.96M | +$1.96M | +75,000 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $1K | +$994 | +38 | New |
|
BBP Hedge Fund Activity: Q4 2014 in Review
2 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q4 2014, worth a combined $1.96M.
Buyers outnumbered sellers: 2 funds opened new BBP positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $1.96M.
- 2 institutional investors held Virtus Biotech ETF (BBP) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $1.96M of Virtus Biotech ETF stock for Q4 2014.
- 2 funds opened new Virtus Biotech ETF positions in Q4 2014 and 0 closed out, a net change of +2 holders.
- The largest Virtus Biotech ETF buyer in Q4 2014 was Deutsche Bank, an estimated $1.96M added.
Based on aggregated 13F filings for Q4 2014.